当前位置: 首页 > 期刊 > 《风湿病与关节炎》 > 20203
编号:13500938
RAPID3在类风湿关节炎患者中的临床应用价值探讨(4)
http://www.100md.com 2020年3月1日 《风湿病与关节炎》 20203
     [11] 楊闵,王英,谢其冰,等.MDHAQ用于类风湿关节炎患者病情评估的临床价值分析[J].四川大学学报(医学版),2015,46(2):285-288.

    [12] QOROLLI M,HUNDOZI-HYSENAJ H,REXHEPI S,et al.RAPID3 scores and hand outcome measurements in RA patients:a preliminary study[J].Clin Rheumatol,2017,36(6):1379-1385.

    [13] MU?OZ JGB,GIRALDO RB,SANTOS AM,et al.Correlation between rapid-3,DAS28,CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis[J].Clin Rheumatol,2017,36(5):1143-1148.

    [14] ZHANG X,XIE A,WANG Y,et al.Performance of routine assessment of patient index data 3(RAPID3) in monitoring disease activity of Chinese rheumatoid arthritis patients[J].Int J Rheum Dis,2018,21(11):1940-1945.

    [15] GENG Y,HAN J,DENG X,et al.Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission:experience from a Chinese cohort[J].Clin Rheumatol,2014,33(8):1061-1066.

    [16] PINCUS T,SWEARINGEN CJ,BERGMAN M,et al.RAPID3(Routine Assessment of Patient Index Data 3),a rheumatoid arthritis index without formal joint counts for routine care:proposed severity categories compared to disease activity score and clinical disease activity index categories[J].J Rheumatol,2008,35(11):2136-2147.

    收稿日期:2019-08-07;修回日期:2019-11-04, 百拇医药(李灿 王莘智)
上一页1 2 3 4